efectos cardiovasculares de fingolimod en el tratamiento de la esclerosis múltiple
Clicks: 126
ID: 188653
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
126 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #69 of 128 articles by views in applied clay science
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 128 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Fingolimod es un medicamento modificador de la enfermedad para pacientes con esclerosis múltiple de tipo recaída remisión; la molécula es un análogo de esfingosina fosfato que debido a su mecanismo de acción, produce en 0,5% de los pacientes, una disminución de la frecuencia cardíaca durante la administración de la primera dosis y un aumento leve de la presión arterial al segundo mes de tratamiento. En este articulo se revisan los mecanismos celulares por los cuales fingolimod causa estos eventos y se reportan recomendaciones de seguridad basados en la US Food and Drug Administration (FDA) para el inicio de pacientes en tratamiento con este medicamento.
| Reference Key |
msc2013revistaefectos
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Miguel A. Urina, MD., MSc;Catalina Rojas, MSc;Daniela Urina, MD |
| Journal | applied clay science |
| Year | 2013 |
| DOI |
10.1016/S0120-5633(13)70044-5
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.